Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2019, XXV/2: 083-089 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2019, XXV/2: 083-089

Title: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in the evaluation of one-year outcomes of omalizumab treatment in severe allergic asthma 

Authors: Jarzębska P, Hermanowicz-Salamon J. 

More details

06-02-2019

0,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in the evaluation of one-year outcomes of omalizumab treatment in severe allergic asthma

Jarzębska P1, Hermanowicz-Salamon J2.

Medical University of Warsaw, Poland: 1Students Scientific Association “Alveolus”; 2Chair and Department of Internal Medicine, Pulmonary Diseases and Allergology

International Review of Medical Practice, 2019; Vol. 25, No. 2, 083

Omalizumab is recommended as add-on therapy for patients with severe allergic asthma. Quality of life questionnaires: mini- AQLQ (mini-Asthma Quality of Life Questionaire) and RQLQ (Rhinoconjunctivitis Quality of life Questionnaire) were developed to measure the impact of these diseases on life. The aim of study was to assess of the utility of RQLQ in the evaluation of the effectiveness of omalizumab treatment. Material and methods. 12 patients with severe asthma (10 F), mean age 48±8.27 y qualified for anti-IgE treatment were analyzed. ACQ (Asthma Control Questionnaire), mini-AQLQ and RQLQ were analysed at three time points: at baseline, prior to treatment onset, after 16 weeks, and after one year of treatment. RQLQ was analysed in detail with special attention to the changes in the specific domains. Results. Omalizumab treatment was clinically effective, ACQ scores and mean ICS dose were reduced at the third point of observation (p < 0.05). Patients achieved statistically significant improvement in mini-AQLQ and RQLQ scores in the second and in third time point of treatment. The biggest improvement in RQLQ score was observed already at the second time point, particularly in the domain of: activity limitation, non-nose/eye symptoms and emotions. The nose symptoms improved after one year in the third time point of observation. Conclusions. Omalizumab treatment improves quality of life measured by AQLQ and RQLQ. RQLQ may serve as an additional, useful tool in evaluation of efficacy of anti-IgE treatment in severe allergic asthma.

Key words: omalizumab, severe allergic asthma, allergic rhinitis